MRAs in CKD: Lessons from a Scientist, an Investigator, and a Trialist
Steroidal mineralocorticoid receptor antagonists (MRA) have been around for decades and were expected to protect against diabetic kidney disease (DKD), as other blockers of the renin-angiotensin aldosterone system (RAS) did. These benefits were not observed, however, until the development of the non-steroidal MRA, finerenone, which reduced DKD progression in patients on RAS blockade in the FIDELIO study. This webinar reviews cell biology relevant to MRAs and DKD, presents official highlights from the FIDELIO team, and takes an independent dive into the trial and implications for practice.
- Learn about the mechanisms of DKD and the potential of MRAs
- Learn about the outcome of the FIDELIO clinical trial
- Understand any implications of FIDELIO’s design and sub-group analyses for clinical practice
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. Bakris GL, et al N Engl J Med. 2020 Dec 3;383(23):2219-2229
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Agarwal R, et al Eur Heart J. 2021 Jan 7;42(2):152-161
This webinar kicks off a series aiming at presenting the outcomes of the FIDELIO and FIGARO trials and discussing how their results may impact future clinical practice. Book your calendars already!
The registration links to the next webinars will follow soon.